Brain Navi’s NaoTrac Wins India’s CDSCO Approval, Targeting 1.4B Population Market
【March 11, 2026 – Zhubei, Taiwan】 Brain Navi Biotechnology, a leader in precision surgical navigation robotics technology, announced today that its flagship NaoTrac neurosurgical navigation robot has officially received medical device approval from India’s CDSCO (Central Drugs Standard Control Organization). Following regulatory clearances such as CE Mark, US FDA and Taiwan FDA, this milestone marks Brain Navi’s strategic entry into one of the world’s fastest-growing major economies and represents a critical breakthrough in the company’s global expansion, set to drive strong revenue momentum.
India, the world's fourth-largest economy, is experiencing explosive growth in its medical device market, with a CAGR of 13.2%.
India is expected to account for 17% of global economic growth, making it the second-largest contributor worldwide. According to the IMF, nominal GDP has exceeded US$ 4 trillion, with a robust 7.3% growth rate expected in FY26 (IMF, 2026). In the neurosurgery devices market, the Indian market size was 14.91 billion in the base year 2025 and is projected to grow at a 13.2% CAGR by 2031, indicating strong market expansion (DiMarket, 2026).
However, the healthcare system faces a severe structural imbalance in surgical expertise. With nearly 80% of neurosurgeons concentrated in Tier-1 cities like Delhi and Mumbai, regional areas often suffer from a deficit of only three neurosurgeons per million people, making the adoption of high-accuracy medicine a clinical necessity. In these underserved areas, the implementation of high-precision surgical robotics is no longer a luxury, but a clinical necessity to bridge the gap in specialist care.
Digital Empowerment Breaks Barriers to Healthcare: Optimizing Surgical Efficiency and Democratizing Access
Brain Navi emphasizes that NaoTrac serves as a high-precision surgical assistant for neurosurgeons. Utilizing proprietary “machine vision” and in-house algorithms, the system achieves rapid, non-invasive patient registration, establishing a strong technical moat. NaoTrac’s autonomous navigation flattens the learning curve for complex procedures allowing regional medical centers to safely and consistently perform high-stakes surgeries, such as brain tumor biopsies and ablations, blood clot drainages, or functional surgery.
Furthermore, NaoTrac’s streamlined setup minimizes pre-operative preparation, significantly boosting surgical throughput and hospital operational efficiency. This efficiency is key to decentralizing high-quality neurosurgical care, moving it from saturated metropolitan hubs to underserved regional populations
North-South Dual-Arrow Strategy: A Commitment to Safeguarding Life
To ensure deep market penetration, Brain Navi has initiated a “North-South” dual-track distribution strategy, with the initial phase being led by our partners in the South. Brain Navi envisions NaoTrac not only as a surgeon’s most precise tool but as a steadfast guardian of health.
By increasing the accessibility of advanced surgical navigation, Brain Navi is providing more families with safer, more precise treatment options for critical neurological conditions. In fulfilling its mission “to improve accuracy, streamline surgical procedures and reduce learning curves.”, Brain Navi continues to build long-term, stable value for its shareholders.
